Nano-hydroxyapatite radiolabeled with radium dichloride [ 223 Ra] RaCl 2 for bone cancer targeted alpha therapy: In vitro assay and radiation effect on the nanostructure

The use of targeted alpha therapy (TAT) for bone cancer is increasing each year. Among the alpha radionuclides, radium [ Ra]Ra is the first one approved for bone cancer metastasis therapy. The development of novel radiopharmaceutical based on [ Ra]Ra is essential to continuously increase the arsenal...

Full description

Saved in:
Bibliographic Details
Published inColloids and surfaces, B, Biointerfaces Vol. 223; p. 113174
Main Authors Gemini-Piperni, Sara, Ricci-Junior, Eduardo, İlem-Özdemir, Derya, da Silva Batista, Beatriz, Alencar, Luciana Magalhães Rebelo, Rossi, Alexandre Malta, Santos-Oliveira, Ralph
Format Journal Article
LanguageEnglish
Published Netherlands 01.03.2023
Subjects
Bone Neoplasms - drug therapy
Humans
Nanostructures
Osteosarcoma - drug therapy
Radiopharmaceuticals
Radium - chemistry
Radium - therapeutic use
Targeted alpha therapy
Radiopharmaceutical
Osteosarcoma
Online AccessGet full text

Cover

More Information
Summary:The use of targeted alpha therapy (TAT) for bone cancer is increasing each year. Among the alpha radionuclides, radium [ Ra]Ra is the first one approved for bone cancer metastasis therapy. The development of novel radiopharmaceutical based on [ Ra]Ra is essential to continuously increase the arsenal of new TAT drugs. In this study we have developed, characterized, and in vitro evaluated [ Ra] Ra-nano-hydroxyapatite. The results showed that [ Ra] Ra-nano-hydroxyapatite has a dose-response relationship for osteosarcoma cells and a safety profile for human fibroblast cells, corroborating the application as a radiopharmaceutical.
ISSN:1873-4367